National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Venetoclax (Venclyxto®)

Venetoclax monotherapy is indicated for the treatment of chronic lymphocytic leukaemia (CLL)


Rapid Review

Commenced Completed Outcome
03/01/2017 08/02/2017 Full HTA not recommended until further evidence available
08/05/2018 21/06/2018 Following a resubmission of the rapid review a full pharmacoeconomic assessment is recommended on the basis of the proposed price, which is not comparable with current available therapies.

The HSE has approved reimbursement following confidential price negotiations – December 2018.